ReviewESC heart failure2018
Metabolic disorders in heart failure and cancer.
Review in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differences in peak oxygen uptake in heart failure patients with and without cachexia: A systematic review and meta-analysis.Physiological reports · 2025Pooled it
- Highlights in heart failure.ESC heart failure · 2019Pooled it
- Economic Evaluation of Individualized Nutritional Support for Hospitalized Patients with Chronic Heart Failure.Nutrients · 2022Trial
- The Sirtuin Network: Linking NADDiabetes/metabolism research and reviews · 2026Review
- Multi-trait association analysis reveals shared genetic architecture between lung cancer and cardiometabolic diseases.iScience · 2025Article
- Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.European journal of heart failure · 2025Article
- Patterns in mortality associated with heart failure and lung cancer among older adults in the United States: An analysis of 20 years.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- miR-221/222-3p act as potential circulating factors in heart failure to stimulate cancer progression.Frontiers in oncology · 2025Article
- Healthcare on the brink: navigating the challenges of an aging society in the United States.npj aging · 2024Review
- Mendelian randomization combined with multi-omics explores the relationship between heart failure and cancer.Journal of Cancer · 2024Article
- Article
- Plasma metabolomic analysis reveals the therapeutic effects of Jiashen tablets on heart failure.Frontiers in cardiovascular medicine · 2022Article
- A year in heart failure: an update of recent findings.ESC heart failure · 2021Review
- Panax quinquefolium saponin Optimizes Energy Homeostasis by Modulating AMPK-Activated Metabolic Pathways in Hypoxia-Reperfusion Induced Cardiomyocytes.Chinese journal of integrative medicine · 2021Article
- Appetite and Nutritional Status as Potential Management Targets in Patients with Heart Failure with Reduced Ejection Fraction-The Relationship between Echocardiographic and Biochemical Parameters and Appetite.Journal of personalized medicine · 2021Article
- Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers.Journal of cachexia, sarcopenia and muscle · 2021Article
- Heart failure in the last year: progress and perspective.ESC heart failure · 2020Review
- Blocking myostatin: muscle mass equals muscle strength?Journal of cachexia, sarcopenia and muscle · 2020Article
- Preserved Skeletal Muscle Mitochondrial Function, Redox State, Inflammation and Mass in Obese Mice with Chronic Heart Failure.Nutrients · 2020Article
- [Tumor effects on the heart and circulation].Der Internist · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In an aging population, the number of patients affected by heart failure and cancer is constantly increasing and together these two conditions account for more than 50% of all deaths worldwide. Both diseases share similar risk factors including smoking, obesity, and hypertension. Presenting symptoms may also be similar, with patients frequently complaining of dyspnea, fatigue, and anorexia. Many affected patients, especially those with more advanced heart failure or cancer, suffer also from metabolic disorders. These can lead eventually to muscle wasting, sarcopenia, and cachexia. These complications are associated with increased morbidity, a poorer quality of life, a worse prognosis and indeed they represent an independent risk factor for the advancement of the underlying disease itself. Very few therapeutic options have been established to treat these co-morbidities. For sarcopenia the only validated treatment is resistance training. Moreover, there is currently no guideline recommended therapy for the treatment of cachexia. New treatment strategies are urgently needed to prevent and treat muscle and wasting disorders in patients with chronic diseases such as cancer and chronic heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.